275 related articles for article (PubMed ID: 26951309)
1. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
Powles T; Lackner MR; Oudard S; Escudier B; Ralph C; Brown JE; Hawkins RE; Castellano D; Rini BI; Staehler MD; Ravaud A; Lin W; O'Keeffe B; Wang Y; Lu S; Spoerke JM; Huw LY; Byrtek M; Zhu R; Ware JA; Motzer RJ
J Clin Oncol; 2016 May; 34(14):1660-8. PubMed ID: 26951309
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure-Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor).
Moein A; Jin JY; Wright MR; Wong H
J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38639108
[TBL] [Abstract][Full Text] [Related]
3. Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
Werter IM; Huijts CM; Lougheed SM; Hamberg P; Polee MB; Tascilar M; Los M; Haanen JBAG; Helgason HH; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 May; 68(5):787-798. PubMed ID: 30756132
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
Atkinson BJ; Cauley DH; Ng C; Millikan RE; Xiao L; Corn P; Jonasch E; Tannir NM
BJU Int; 2014 Mar; 113(3):376-82. PubMed ID: 24053120
[TBL] [Abstract][Full Text] [Related]
5. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
Treilleux I; Arnedos M; Cropet C; Wang Q; Ferrero JM; Abadie-Lacourtoisie S; Levy C; Legouffe E; Lortholary A; Pujade-Lauraine E; Bourcier AV; Eymard JC; Spaeth D; Bachelot T
Ann Oncol; 2015 Jan; 26(1):120-125. PubMed ID: 25361980
[TBL] [Abstract][Full Text] [Related]
6. Differentiating mTOR inhibitors in renal cell carcinoma.
Pal SK; Quinn DI
Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
McGregor BA; Xie W; Adib E; Stadler WM; Zakharia Y; Alva A; Michaelson MD; Gupta S; Lam ET; Farah S; Nassar AH; Wei XX; Kilbridge KL; Harshman L; Signoretti S; Sholl L; Kwiatkowski DJ; McKay RR; Choueiri TK
JCO Precis Oncol; 2022 Feb; 6():e2100448. PubMed ID: 35171658
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Ryan CW; Tangen CM; Heath EI; Stein MN; Meng MV; Alva AS; Pal SK; Puzanov I; Clark JI; Choueiri TK; Agarwal N; Uzzo RG; Haas NB; Synold TW; Plets M; Vaishampayan UN; Shuch BM; Thompson IM; Lara PN
Lancet; 2023 Sep; 402(10407):1043-1051. PubMed ID: 37524096
[TBL] [Abstract][Full Text] [Related]
9. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.
Ray-Coquard I; Favier L; Weber B; Roemer-Becuwe C; Bougnoux P; Fabbro M; Floquet A; Joly F; Plantade A; Paraiso D; Pujade-Lauraine E
Br J Cancer; 2013 May; 108(9):1771-7. PubMed ID: 23612453
[TBL] [Abstract][Full Text] [Related]
10. Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer.
Thiery-Vuillemin A; Curtit E; Maurina T; Montange D; Succi C; NGuyen T; Kim S; Montcuquet P; Pivot X; Royer B
Ann Oncol; 2012 Nov; 23(11):2992-2993. PubMed ID: 23071263
[No Abstract] [Full Text] [Related]
11. A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.
Pal S; Azad A; Bhatia S; Drabkin H; Costello B; Sarantopoulos J; Kanesvaran R; Lauer R; Starodub A; Hauke R; Sweeney CJ; Hahn NM; Sonpavde G; Richey S; Breen T; Kremmidiotis G; Leske A; Doolin E; Bibby DC; Simpson J; Iglesias J; Hutson T
Clin Cancer Res; 2015 Aug; 21(15):3420-7. PubMed ID: 25788492
[TBL] [Abstract][Full Text] [Related]
12. Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors.
Kopecky J; Kubecek O; Buchler T; Melichar B; Poprach A; Zemanova M; Katolicka J; Kiss I; Hajek J; Studentova H; Spisarova M
In Vivo; 2021; 35(5):2981-2990. PubMed ID: 34410998
[TBL] [Abstract][Full Text] [Related]
13. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
Haas-Kogan DA; Aboian MS; Minturn JE; Leary SES; Abdelbaki MS; Goldman S; Elster JD; Kraya A; Lueder MR; Ramakrishnan D; von Reppert M; Liu KX; Rokita JL; Resnick AC; Solomon DA; Phillips JJ; Prados M; Molinaro AM; Waszak SM; Mueller S
J Clin Oncol; 2024 Feb; 42(4):441-451. PubMed ID: 37978951
[TBL] [Abstract][Full Text] [Related]
14. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.
Albiges L; Chamming's F; Duclos B; Stern M; Motzer RJ; Ravaud A; Camus P
Ann Oncol; 2012 Aug; 23(8):1943-1953. PubMed ID: 22689175
[TBL] [Abstract][Full Text] [Related]
15. mTOR Inhibition Prolongs Survival and Has Beneficial Effects on Heart Function After Onset of Lamin A/C Gene Mutation Cardiomyopathy in Mice.
Wu W; Jin Q; Östlund C; Tanji K; Shin JY; Han J; Leu CS; Kushner J; Worman HJ
Circ Heart Fail; 2024 Apr; 17(4):e011110. PubMed ID: 38567527
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of everolimus in korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor.
Park K; Lee JL; Ahn JH; Lee KH; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Res Treat; 2014 Oct; 46(4):339-47. PubMed ID: 25036572
[TBL] [Abstract][Full Text] [Related]
17. mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy.
Caliò A; Marletta S; Settanni G; Rizzo M; Gobbo S; Pedron S; Stefanizzi L; Munari E; Brunelli M; Marcolini L; Pesci A; Fratoni S; Pierconti F; Raspollini MR; Marchetti A; Doglioni C; Amin MB; Porta C; Martignoni G
Virchows Arch; 2023 Dec; 483(6):821-833. PubMed ID: 37938323
[TBL] [Abstract][Full Text] [Related]
18. Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.
Burnett AK; Das Gupta E; Knapper S; Khwaja A; Sweeney M; Kjeldsen L; Hawkins T; Betteridge SE; Cahalin P; Clark RE; Hills RK; Russell NH;
Haematologica; 2018 Oct; 103(10):1654-1661. PubMed ID: 29976746
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin inhibition impacts energy homeostasis and induces sex-specific body weight loss in humans.
Mannaa M; Pfennigwerth P; Fielitz J; Gollasch M; Boschmann M
J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2757-2767. PubMed ID: 37897143
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma.
Alesini D; Mosillo C; Naso G; Cortesi E; Iacovelli R
Ther Adv Urol; 2015 Oct; 7(5):286-94. PubMed ID: 26425143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
